http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 20 Aug 2026 16:05:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Aug+19++Filed+by%3A+Goin+Kathleen/26956163.html si-local-file:///var/storage/secattach/20260820/26956163.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Aug+19++Filed+by%3A+Goin+Kathleen/26956163.html Thu, 20 Aug 2026 16:05:00 -0400 O.00285300 PVLA http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Aug+19++Filed+by%3A+Goin+Kathleen/26956163.html si-local-file:///var/storage/secattach/20260820/26956163.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Aug+19++Filed+by%3A+Goin+Kathleen/26956163.html Thu, 20 Aug 2026 16:05:00 -0400 O.00285300 PVLA http://www.streetinsider.com/SEC+Filings/Form++144++++++++PALVELLA+THERAPEUTICS%2C+++++++++++++++++Filed+by%3A+Goin+Kathleen/26950894.html si-local-file:///var/storage/secattach/20260819/26950894.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++PALVELLA+THERAPEUTICS%2C+++++++++++++++++Filed+by%3A+Goin+Kathleen/26950894.html Wed, 19 Aug 2026 16:57:00 -0400 O.00285300 PVLA http://www.streetinsider.com/SEC+Filings/Form++144++++++++PALVELLA+THERAPEUTICS%2C+++++++++++++++++Filed+by%3A+Goin+Kathleen/26950894.html si-local-file:///var/storage/secattach/20260819/26950894.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++PALVELLA+THERAPEUTICS%2C+++++++++++++++++Filed+by%3A+Goin+Kathleen/26950894.html Wed, 19 Aug 2026 16:57:00 -0400 O.00285300 PVLA http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PALVELLA+THERAPEUTICS%2C+++++++++++++++++Filed+by%3A+First+Light+Asset+Management%2C+LLC/26931830.html si-local-file:///var/storage/secattach/20260814/26931830.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PALVELLA+THERAPEUTICS%2C+++++++++++++++++Filed+by%3A+First+Light+Asset+Management%2C+LLC/26931830.html Fri, 14 Aug 2026 16:40:00 -0400 O.00285300 PVLA http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PALVELLA+THERAPEUTICS%2C+++++++++++++++++Filed+by%3A+First+Light+Asset+Management%2C+LLC/26931830.html si-local-file:///var/storage/secattach/20260814/26931830.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PALVELLA+THERAPEUTICS%2C+++++++++++++++++Filed+by%3A+First+Light+Asset+Management%2C+LLC/26931830.html Fri, 14 Aug 2026 16:40:00 -0400 O.00285300 PVLA http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PALVELLA+THERAPEUTICS%2C+++++++++++++++++Filed+by%3A+BIOTECHNOLOGY+VALUE+FUND+L+P/26931210.html si-local-file:///var/storage/secattach/20260814/26931210.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PALVELLA+THERAPEUTICS%2C+++++++++++++++++Filed+by%3A+BIOTECHNOLOGY+VALUE+FUND+L+P/26931210.html Fri, 14 Aug 2026 16:27:00 -0400 O.00285300 PVLA http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PALVELLA+THERAPEUTICS%2C+++++++++++++++++Filed+by%3A+BIOTECHNOLOGY+VALUE+FUND+L+P/26931210.html si-local-file:///var/storage/secattach/20260814/26931210.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13GA++PALVELLA+THERAPEUTICS%2C+++++++++++++++++Filed+by%3A+BIOTECHNOLOGY+VALUE+FUND+L+P/26931210.html Fri, 14 Aug 2026 16:27:00 -0400 O.00285300 PVLA http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++PALVELLA+THERAPEUTICS%2C+++++++++++++++++Filed+by%3A+PRUDENTIAL+FINANCIAL+INC/26896986.html si-local-file:///var/storage/secattach/20260810/26896986.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++PALVELLA+THERAPEUTICS%2C+++++++++++++++++Filed+by%3A+PRUDENTIAL+FINANCIAL+INC/26896986.html Mon, 10 Aug 2026 14:12:00 -0400 O.00285300 PVLA http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++PALVELLA+THERAPEUTICS%2C+++++++++++++++++Filed+by%3A+PRUDENTIAL+FINANCIAL+INC/26896986.html si-local-file:///var/storage/secattach/20260810/26896986.html http://www.streetinsider.com/SEC+Filings/Form++SCHEDULE+13G++PALVELLA+THERAPEUTICS%2C+++++++++++++++++Filed+by%3A+PRUDENTIAL+FINANCIAL+INC/26896986.html Mon, 10 Aug 2026 14:12:00 -0400 O.00285300 PVLA http://www.streetinsider.com/Press+Releases/Palvella+Therapeutics+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870306.html <p align="justify">WAYNE, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, announced today that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 3:30 p.m. ET.</p> <p align="justify">A live webcast of the fireside chat will be available on the <a http://www.streetinsider.com/Press+Releases/Palvella+Therapeutics+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870306.html Wed, 05 Aug 2026 07:30:00 -0400 A.06822034 O.00285300 O.20026344 PVLA http://www.streetinsider.com/Press+Releases/Palvella+Therapeutics+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870306.html <p align="justify">WAYNE, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, announced today that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 3:30 p.m. ET.</p> <p align="justify">A live webcast of the fireside chat will be available on the <a http://www.streetinsider.com/Press+Releases/Palvella+Therapeutics+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870306.html Wed, 05 Aug 2026 07:30:00 -0400 A.06822034 O.00285300 O.20026344 PVLA http://www.streetinsider.com/Press+Releases/Palvella+Therapeutics+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870306.html <p align="justify">WAYNE, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, announced today that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 3:30 p.m. ET.</p> <p align="justify">A live webcast of the fireside chat will be available on the <a http://www.streetinsider.com/Press+Releases/Palvella+Therapeutics+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870306.html Wed, 05 Aug 2026 07:30:00 -0400 A.06822034 O.00285300 O.20026344 PVLA http://www.streetinsider.com/Press+Releases/Palvella+Therapeutics+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870306.html <p align="justify">WAYNE, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, announced today that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 3:30 p.m. ET.</p> <p align="justify">A live webcast of the fireside chat will be available on the <a http://www.streetinsider.com/Press+Releases/Palvella+Therapeutics+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870306.html Wed, 05 Aug 2026 07:30:00 -0400 A.06822034 O.00285300 O.20026344 PVLA http://www.streetinsider.com/Globe+Newswire/Palvella+Therapeutics+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870306.html <p align="justify">WAYNE, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, announced today that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 3:30 p.m. ET.</p> <p align="justify">A live webcast of the fireside chat will be available on the <a http://www.streetinsider.com/Globe+Newswire/Palvella+Therapeutics+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870306.html Wed, 05 Aug 2026 07:30:00 -0400 A.06822034 O.00285300 O.20026344 PVLA http://www.streetinsider.com/Globe+Newswire/Palvella+Therapeutics+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870306.html <p align="justify">WAYNE, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, announced today that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 3:30 p.m. ET.</p> <p align="justify">A live webcast of the fireside chat will be available on the <a http://www.streetinsider.com/Globe+Newswire/Palvella+Therapeutics+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870306.html Wed, 05 Aug 2026 07:30:00 -0400 A.06822034 O.00285300 O.20026344 PVLA http://www.streetinsider.com/Globe+Newswire/Palvella+Therapeutics+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870306.html <p align="justify">WAYNE, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, announced today that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 3:30 p.m. ET.</p> <p align="justify">A live webcast of the fireside chat will be available on the <a http://www.streetinsider.com/Globe+Newswire/Palvella+Therapeutics+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870306.html Wed, 05 Aug 2026 07:30:00 -0400 A.06822034 O.00285300 O.20026344 PVLA http://www.streetinsider.com/Globe+Newswire/Palvella+Therapeutics+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870306.html <p align="justify">WAYNE, Pa., Aug. 05, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or the “Company”) (Nasdaq: PVLA), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare skin diseases and vascular malformations for which there are no U.S. Food and Drug Administration (FDA)-approved therapies, announced today that Wes Kaupinen, Founder and Chief Executive Officer of Palvella, will participate in a fireside chat at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 3:30 p.m. ET.</p> <p align="justify">A live webcast of the fireside chat will be available on the <a http://www.streetinsider.com/Globe+Newswire/Palvella+Therapeutics+to+Participate+in+the+Canaccord+Genuity+46th+Annual+Growth+Conference/26870306.html Wed, 05 Aug 2026 07:30:00 -0400 A.06822034 O.00285300 O.20026344 PVLA http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++PALVELLA+THERAPEUTICS%2C+++++++++++++++/26866761.html si-local-file:///var/storage/secattach/20260804/26866761.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++PALVELLA+THERAPEUTICS%2C+++++++++++++++/26866761.html Tue, 04 Aug 2026 16:20:00 -0400 O.00285300 PVLA http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++PALVELLA+THERAPEUTICS%2C+++++++++++++++/26866761.html si-local-file:///var/storage/secattach/20260804/26866761.html http://www.streetinsider.com/SEC+Filings/Form++S-8++++++++PALVELLA+THERAPEUTICS%2C+++++++++++++++/26866761.html Tue, 04 Aug 2026 16:20:00 -0400 O.00285300 PVLA http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Jun+30/26861736.html si-local-file:///var/storage/secattach/20260804/26861736.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Jun+30/26861736.html Tue, 04 Aug 2026 07:52:00 -0400 O.00285300 PVLA http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Jun+30/26861736.html si-local-file:///var/storage/secattach/20260804/26861736.html http://www.streetinsider.com/SEC+Filings/Form++10-Q+++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Jun+30/26861736.html Tue, 04 Aug 2026 07:52:00 -0400 O.00285300 PVLA http://www.streetinsider.com/Earnings/Palvella+Therapeutics+%28PVLA%29+Misses+Q2+EPS+by+36c/26861693.html <p>Palvella Therapeutics (NASDAQ: PVLA) reported Q2 EPS of ($1.52), $0.36 worse than the analyst estimate of ($1.16).</p><p>For earnings history and earnings-related data on Palvella Therapeutics (PVLA) <a href="http://www.streetinsider.com/ec_earnings.php?q=PVLA">click here</a>.</p> http://www.streetinsider.com/Earnings/Palvella+Therapeutics+%28PVLA%29+Misses+Q2+EPS+by+36c/26861693.html Tue, 04 Aug 2026 07:39:53 -0400 PVLA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Aug+04/26861625.html si-local-file:///var/storage/secattach/20260804/26861625.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Aug+04/26861625.html Tue, 04 Aug 2026 07:31:00 -0400 O.00285300 PVLA http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Aug+04/26861625.html si-local-file:///var/storage/secattach/20260804/26861625.html http://www.streetinsider.com/SEC+Filings/Form++8-K++++++++PALVELLA+THERAPEUTICS%2C++++For%3A+Aug+04/26861625.html Tue, 04 Aug 2026 07:31:00 -0400 O.00285300 PVLA